Clovis Oncology (CLVS) Misses Q3 EPS by 8c; Reports $171.9M in Cash and Cash Equivalents

Clovis Oncology (NASDAQ: CLVS) reported Q3 EPS of ($0.56), $0.08 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $37.9 million versus the consensus estimate of $39.09 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M